Amplia Therapeutics with CEO Chris Burns

About this episode

In this episode, CEO Chris Burns discusses Amplia Therapeutics' innovative approach to treating pancreatic cancer and the challenges associated with current treatment options.

00:00 – Intro & welcome to Chris Burns, CEO of Amplia 02:00 – Why pancreatic cancer is so deadly & hard to diagnose 06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX 11:20 – Side effects & challenges with chemotherapy 15:00 – Why pancreatic cancer is difficult to treat (fibrosis & mutations) 19:00 – Amplia’s approach: FAK inhibitors and how they work 23:00 – History of FAK inhibitors & Amplia’s drug development story 27:00 – ACCENT trial design and early results (response rate, PFS) 32:00 – Complete responses & long-term responders (12–18+ months) 36:00 – Next steps: Simplicity trial with FOLFIRINOX 38:30 – Path to registrational trial & FDA fast track 41:00 – Combination opportunities: KRAS inhibitors & ADCs 43:00 – Commercial strategy, pricing, partnerships 44:30 – Wrap-up & final thoughts

People in this episode

Guest: Chris Burns

Topics covered

• pancreatic cancer
• treatment options
• drug development
• clinical trials
• FAK inhibitors

Keywords

• pancreatic cancer
• FAK inhibitors
• ACCENT trial
• chemotherapy
• FDA fast track
• KRAS inhibitors
• commercial strategy

Mentioned in this episode

Products: Gem/Abraxane, Gem, Abraxane, FOLFIRINOX

More episodes of Frazis Capital Podcast

• #100: Market Update & Launch of ROAR · June 12, 2026 · 32 min
• #99: ETF Launch - ASX:ROAR · June 2, 2026 · 37 min
• #98: AI Agents, Software Collapse & the Next Tech Cycle · February 2, 2026 · 39 min
• #97: AI Has Entered the Takeoff Phase · January 12, 2026 · 21 min
• #96: 99% of people missed it. You have 33 minutes to catch up. · January 5, 2026 · 33 min
• #94: Nvidia’s Red Flags, NeoCloud Bubble & the Quiet Quant Crash · December 28, 2025 · 39 min